BACKGROUND: We conducted this meta-analysis to systematically review and analyze the clinical benefits of angiotensin receptor blocker (ARB) combined with @entity460 channel blocker (CCB) following ineffective CCB monotherapy. METHODS: PubMed was searched for articles published until August 2015. Randomized controlled trials (RCTs) evaluating the clinical benefits of ARB combined with CCB following ineffective CCB monotherapy were included. The primary efficacy endpoint of the studies was normal rate of blood pressure, the secondary efficacy endpoints were the response rate and change in blood pressure from baseline. The safety endpoint of the studies was incidence of adverse events. Differences are expressed as relative risks (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes and @entity353 ( @entity353 ) with 95% CIs for continuous outcomes. Heterogeneity across studies was tested by using the I(2) statistic. RESULTS: Seven RCTs were included and had sample sizes ranging from 185 to 1,183 subjects (total: 3,909 subjects). The pooled analysis showed that the on-target rate of @entity101 treatment was significantly higher in the @entity3591 + ARB group than in the @entity3591 monotherapy group (RR =1.59; 95% CI, 1.31-1.91; P<0.01). The response rate of systolic blood pressure (SBP) (RR =1.28; 95% CI, 1.04-1.58; P<0.01) and diastolic blood pressure (DBP) (RR =1.27; 95% CI, 1.12-1.44; P=0.04) were significantly higher in the @entity3591 + ARB group than in the @entity3591 monotherapy group. The change in SBP (RR =-3.56; 95% CI, -7.76-0.63; P=0.10) and DBP (RR =-3.03; 95% CI, -6.51-0.45; P=0.09) were higher in @entity101 @entity1 receiving @entity3591 + ARB but the difference did not reach statistical significance. ARB + @entity3591 treatment carried a lower risk of adverse events relative to @entity3591 monotherapy (RR =0.88; 95% CI, 0.80-0.96; P<0.01). CONCLUSIONS: The results of our meta-analysis demonstrate that adding an ARB to CCB after initial ineffective CCB monotherapy, significantly improved blood pressure control and the percentage of on-target @entity101 treatment with significantly reduced incidence of adverse events compared with continued CCB monotherapy.

Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a XXXX channel blocker (CCB) following ineffective CCB monotherapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity353 :: ('MESH:D015431', 'Disease') :: ['WMDs', 'weighted mean differences'] @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']
@entity460 :: (MESH:D002118,Chemical) :: ['calcium']
